Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation

In thrombolytic therapy, plasminogen activators (PAs) are still the only group of drug approved to induce thrombolysis, and therefore, critical for treatment of arterial thromboembolism, such as stroke, in the acute phase. Functionalized nanocomposites have attracted great attention in achieving tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yunn-Hwa, Liu, Chih-Hsin, Liang, Yueh, Chen, Jyh-Ping, Wu, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766944/
https://www.ncbi.nlm.nih.gov/pubmed/31546842
http://dx.doi.org/10.3390/molecules24183407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766944/
https://www.ncbi.nlm.nih.gov/pubmed/31546842
http://dx.doi.org/10.3390/molecules24183407

Ejemplares similares